Dynamic structural design of offshore direct-drive wind turbine electrical generators.

Direct-drive permanent magnet generators for multi-MW wind turbines are low speed high torque electrical machines requiring large, heavy and robust structures to maintain the airgap clearance open and stable. The structural mass of radial-flux generators can be estimated at an early phase of the design process. Using distinct approaches, the integrity of a 3 MW electrical machine structure has been addressed from a dynamic perspective by carrying out modal analyses with a view to minimize its mass. A versatile tool has also been developed to help the engineers with the dynamic design of generator disc structures. Conical structures have been analysed and compared with the baseline disc model obtaining very promising results. Potential improvements have been proposed for more ambitious structural designs

LIDAR-assisted feedforward individual pitch control of a 15 MW floating offshore wind turbine

Nacelle‐mounted, forward‐facing light detection and ranging (LIDAR) technology can deliver benefits to rotor speed regulation and loading reductions of floating offshore wind turbines (FOWTs) when assisting with blade pitch control in above‐rated wind speed conditions. Large‐scale wind turbines may be subject to significant variations in structural loads due to differences in the wind profile across the rotor‐swept area. These loading fluctuations can be mitigated by individual pitch control (IPC). This paper presents a novel LIDAR‐assisted feedforward IPC approach that uses each blade's rotor azimuth position to allocate an individual pitch command from a multi‐beam LIDAR. In this study, the source code of OpenFAST wind turbine modelling software was modified to enable LIDAR simulation and LIDAR‐assisted control. The LIDAR simulation modifications were accepted by the National Renewable Energy Laboratory (NREL) and are now present within OpenFAST releases from v3.5 onwards. Simulations of a 15 MW FOWT were performed across the above‐rated wind spectrum. Under a turbulent wind field with an average wind speed of 17 ms−1, the LIDAR‐assisted feedforward IPC delivered up to 54% reductions in the root mean squared errors and standard deviations of key FOWT parameters. Feedforward IPC delivered enhancements of up to 12% over feedforward collective pitch control, relative to the baseline feedback controller. The reductions to the standard deviation and range of the rotor speed may enable structural optimization of the tower, while the reductions in the variations of the loadings present an opportunity for reduced fatigue damage on turbine components and, consequently, a reduction in maintenance expenditure

The ventilation effect on stator convective heat transfer of an axial-flux permanent-magnet machine

This paper investigates the effect of the inlet configuration on cooling for an air-cooled axial-flux permanent-magnet (AFPM) machine. Temperature rises in the stator were measured and compared with results predicted using computational fluid dynamic (CFD) methods linked to a detailed machine loss characterization. It is found that an improved inlet design can significantly reduce the stator temperature rises. Comparison between the validated CFD model results and the values obtained from heat transfer correlations addresses the suitability of those correlations proposed specifically for AFPM machines

Review of magnetic gear technologies and their applications in marine energy

The marine energy industry is in its early stages but has a large potential for growth. One of the most significant challenges is the reduction of operation and maintenance costs. Magnetic gears (MGs) offer the potential for long periods between maintenance intervals due to their frictionless torque transmission which could reduce these costs. This study presents a summary of the state of the art in MG technology and then investigates its potential for marine energy applications. A brief overview is given of the state of the marine energy industry and the environment in which marine energy converters (MECs) operate. A short history of MG development over the past century is then presented followed by a discussion of the leading MG technologies and their relative advantages. In order to demonstrate the potential of MGs in marine applications, the current technologies, i.e. mechanically geared and direct drive machines, are examined in terms of sizing, reliability and economic value using previous studies on a similar technology, namely wind. MGs are applied to four types of MECs to demonstrate how the technology can be incorporated. The potential to deploy at scale and potential obstacles to this are then discussed

Characterisation of proteins in excretory/secretory products collected from salmon lice, Lepeophtheirus salmonis

Background  The salmon louse, Lepeophtheirus salmonis, is an ectoparasitic copepod which feeds on the mucus, skin and blood of salmonid fish species. The parasite can persist on the surface of the fish without any effective control being exerted by the host immune system. Other ectoparasitic invertebrates produce compounds in their saliva, excretions and/or secretions which modulate the host immune responses allowing them to remain on or in the host during development. Similarly, compounds are produced in secretions of L. salmonis which are thought to be responsible for immunomodulation of the host responses as well as other aspects of crucial host-parasite interactions.  Methods  In this study we have identified and characterised the proteins in the excretory/secretory (E/S) products of L. salmonis using LC-ESI-MS/MS.  Results  In total 187 individual proteins were identified in the E/S collected from adult lice and pre-adult sea lice. Fifty-three proteins, including 13 serine-type endopeptidases, 1 peroxidase and 5 vitellogenin-like proteins were common to both adult and pre-adult E/S products. One hundred and seven proteins were identified in the adult E/S but not in the pre-adult E/S and these included serine and cysteine-type endopeptidases, vitellogenins, sphingomyelinase and calreticulin. A total of 27 proteins were identified in pre-adult E/S products but not in adult E/S.  Conclusions  The assigned functions of these E/S products and the potential roles they play in host-parasite interaction is discussed

Viral coinfections in hospitalized coronavirus disease 2019 patients recruited to the international severe acute respiratory and emerging infections consortium WHO clinical characterisation protocol UK study

Background We conducted this study to assess the prevalence of viral coinfection in a well characterized cohort of hospitalized coronavirus disease 2019 (COVID-19) patients and to investigate the impact of coinfection on disease severity. Methods Multiplex real-time polymerase chain reaction testing for endemic respiratory viruses was performed on upper respiratory tract samples from 1002 patients with COVID-19, aged <1 year to 102 years old, recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK study. Comprehensive demographic, clinical, and outcome data were collected prospectively up to 28 days post discharge. Results A coinfecting virus was detected in 20 (2.0%) participants. Multivariable analysis revealed no significant risk factors for coinfection, although this may be due to rarity of coinfection. Likewise, ordinal logistic regression analysis did not demonstrate a significant association between coinfection and increased disease severity. Conclusions Viral coinfection was rare among hospitalized COVID-19 patients in the United Kingdom during the first 18 months of the pandemic. With unbiased prospective sampling, we found no evidence of an association between viral coinfection and disease severity. Public health interventions disrupted normal seasonal transmission of respiratory viruses; relaxation of these measures mean it will be important to monitor the prevalence and impact of respiratory viral coinfections going forward

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1–11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury. Autoantibodies are more common in COVID-19 than controls and some (including against MYL7, UCH-L1, and GRIN3B) are more frequent with altered consciousness. Additionally, convalescent participants with neurological complications show elevated GFAP and NfL, unrelated to attenuated systemic inflammatory mediators and to autoantibody responses. Overall, neurological complications of COVID-19 are associated with evidence of neuroglial injury in both acute and late disease and these correlate with dysregulated innate and adaptive immune responses acutely

Genomic investigations of unexplained acute hepatitis in children

Since its first identification in Scotland, over 1,000 cases of unexplained paediatric hepatitis in children have been reported worldwide, including 278 cases in the UK1. Here we report an investigation of 38 cases, 66 age-matched immunocompetent controls and 21 immunocompromised comparator participants, using a combination of genomic, transcriptomic, proteomic and immunohistochemical methods. We detected high levels of adeno-associated virus 2 (AAV2) DNA in the liver, blood, plasma or stool from 27 of 28 cases. We found low levels of adenovirus (HAdV) and human herpesvirus 6B (HHV-6B) in 23 of 31 and 16 of 23, respectively, of the cases tested. By contrast, AAV2 was infrequently detected and at low titre in the blood or the liver from control children with HAdV, even when profoundly immunosuppressed. AAV2, HAdV and HHV-6 phylogeny excluded the emergence of novel strains in cases. Histological analyses of explanted livers showed enrichment for T cells and B lineage cells. Proteomic comparison of liver tissue from cases and healthy controls identified increased expression of HLA class 2, immunoglobulin variable regions and complement proteins. HAdV and AAV2 proteins were not detected in the livers. Instead, we identified AAV2 DNA complexes reflecting both HAdV-mediated and HHV-6B-mediated replication. We hypothesize that high levels of abnormal AAV2 replication products aided by HAdV and, in severe cases, HHV-6B may have triggered immune-mediated hepatic disease in genetically and immunologically predisposed children

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570